Ensurge Micropower ASA - Financial Report - 4Q 2022
Ensurge Micropower ASA(OSE:ENSU,and OTCIQ: ENMPY), today released its interim report for the 4Q 2022 and the condensed consolidated financial statements as of 31 December 2022 for the Ensurge Micropower ASA group.
Report highlights include:
- Mark Newman, currently an Ensurge board director, replaced Kevin Barber as the interim CEO and has presented the new management action plan to take the company into the commercialization phase
- Received first production order for 150,000 Ensurge microbatteries from the lead customer, an innovator in the digital health market
- Evaluation report of Ensurge microbattery core cells from a strategic partner, a leader in consumer electronics, matched Ensurge’s capacity and energy density calculations
- Presented technical data at the TechBlick conference “Solid-State Batteries: Innovations, Promising Startups, and Future Roadmap,” demonstrating Ensurge microbattery performance including energy density, cycling and charging speed
- Production line converted to the lead production customer’s target form factor and performance requirements
- Continued strong customer interest with 10 new qualified customers added to the pipeline
- New management focused on converting the existing pipeline into paying customers including pushing customers and partners to pay for development work
- A renewed cost cutting exercise will be implemented, targeting 30% reduction in cash burn rate
Interim CEO Mark Newman will discuss the Company's progress via web conference on Thursday, 9 March 2023 at 12:00pm (noon) Central European Time. Ensurge Micropower ASA has delayed the web conference in light of the recent organization change.
About Ensurge Micropower:
Ensurge is Energizing Innovation(TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1-100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports and fitness devices, and IoT sensor solutions that use energy harvesting to power everyday things. The company's state-of-the-art manufacturing facility, located in the heart of Silicon Valley, combines patented process technology and materials innovation with the scale of roll-to-roll production methods to bring the advantages of Ensurge technology to established and expanding markets. Ensurge Micropower ASA ("Ensurge") is a publicly listed company in Norway with corporate headquarters in Oslo and global headquarters in San Jose, California.
Contact Ståle Bjørnstad - Investor Relations
Phone: +47 99 16 76 72 Kevin Barber -
Chief Executive Officer E-mail: Mark.Newman@Ensurge.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities21.3.2023 16:00:00 CET | Press release
Company Announcement No. 16/2023 Copenhagen, 21 March 2023 Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Niels Frederiksen 2. Reason for the notification a) Position/title CEO and member of the Executive Management b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Grant of shares due to vesting of performance share
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation21.3.2023 15:48:10 CET | Press release
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.1 Sandoz
Articles of Association for RTX A/S21.3.2023 15:28:54 CET | Press release
Nørresundby, Denmark, 21 March 2023 Announcement no. 11/2023 Articles of Association for RTX A/S as adopted at the Annual General Meeting on 26 January 2023 and finally adopted at the extraordinary general meeting on 10 March 2023 (cf. company announcement 10/2023) has been registered and published. The Articles of Association are available at the company’s website www.rtx.dk under: Governance => Articles of Association. Questions and further information: CEO Peter Røpke, tel: +45 96 32 23 00 Attachment RTX A-S - Articles of Association 10 March 2023
Vedtægter for RTX A/S21.3.2023 15:28:54 CET | pressemeddelelse
Nørresundby, den 21. marts 2023 Selskabsmeddelelse nr. 11/2023 Vedtægter for RTX A/S som vedtaget på RTX’s ordinære generalforsamling 26. januar 2023 og endeligt vedtaget på selskabets ekstraordinære generalforsamling 10. marts 2023 (jf. selskabsmeddelelse 10/2023) er blevet registreret og offentliggjort. Vedtægterne er tilgængelige på selskabets hjemmeside www.rtx.dk under: Governance => Vedtægter. Spørgsmål og yderligere oplysninger: CEO Peter Røpke, tlf: +45 96 32 23 00. Vedhæftet fil RTX A-S - vedtægter pr. 10. marts 2023
PARKEN Sport & Entertainment A/S - Bestyrelsesændring21.3.2023 15:24:14 CET | pressemeddelelse
William Kvist genopstiller ikke til bestyrelsen på selskabets ordinære generalforsamling den 21. april 2023. William Kvist har været en del af bestyrelsen siden 2019 og var i en periode også fungerende sportslig leder i F.C. København. Vedhæftet fil 09-2023 Bestyrelsesændring